Dr. Beverly Richardson reports

MEDIVOLVE ANNOUNCES RESULTS OF ANNUAL AND SPECIAL SHAREHOLDER MEETING

In accordance with the policies of the NEO Exchange, the nominees listed in Medivolve Inc.'s management information circular dated May 16, 2022, for the 2022 annual and special meeting of shareholders of the company were elected as directors of the company. Of all of the issued and outstanding shares of the company, 21.82 per cent were represented at the meeting.

Detailed results of the vote for the election of directors held at the meeting on June 15, 2022, in Toronto, Ont., are set out in the attached table.

Election of directors

The shareholders approved the election as directors of the persons listed herein based on the following vote.

Shareholders at the meeting also approved the appointment of the company's auditor, McGovern Hurley LLP, the reapproval of the company's rolling stock option plan, name change to Medidoc Inc. or other such name as may be approved by the board of directors, and a consolidation of the company's common shares on the basis of up to 1 to 15.

Medivolve's board of directors would like to express its gratitude to its shareholders for their continued support.

About Medivolve Inc.

Medivolve is a health care technology company that seeks to reinvent the U.S. health care system by leveraging a bespoke telehealth platform, a clinical diagnostic network and a data-driven artificial intelligence framework to improve patient care.

The company was born out of the health care crisis, to rethink, relearn and ultimately reimagine a better way for the health care system to operate. Its network of retail collection sites plays an essential role in recovery by giving all Americans access to fast, accurate and inexpensive clinical services when and where they need them. These centres will also play a pivotal role in diagnostic testing, vaccinations and other point-of-care services. The company is building disruptive technologies to make it easier and faster to identify, treat and prevent medical issues. In doing so, it is working to give patients a holistic and empowered view of their personal health.

The company's long-term mission is to permanently fix systemic issues in the nation's fragmented, overly complex and expensive health care system. Medivolve's next growth phase is about pivoting the model and putting the pieces together to build a profitable, software-as-a-service-based (SaaS) health tech company. Medivolve brings data-driven clinical diagnostics, physician recommendations and prescription medications directly to people, all powered by a singular, streamlined technology network. A powerful, singular purpose unites the company's team: harnessing the transformative power of technology to create healthier lives.

Underpinned by a bespoke, AI-driven (artificial intelligence) platform, the company is developing a stealth system that constantly gets smarter, takes the guesswork out of diagnostics and flags critical health issues immediately to deliver an unparalleled level of personalization for each patient. It is determined to push the boundaries of what is possible -- not just for its business and its shareholders, but for physicians and patients, and the future of health care. The company strives to achieve a continuity of care never seen before, a game-changer for its business and patients in the communities the company serves.

We seek Safe Harbor.